Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
SYN's Cash to Debt is ranked higher than
88% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. SYN: No Debt )
SYN' s 10-Year Cash to Debt Range
Min: 0.02   Max: No Debt
Current: No Debt

F-Score: 2
Z-Score: 78.99
M-Score: -5.57
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Revenue Growth (%) -100.00
SYN's Revenue Growth (%) is ranked lower than
97% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: -0.40 vs. SYN: -100.00 )
SYN' s 10-Year Revenue Growth (%) Range
Min: 0   Max: -100
Current: -100

EBITDA Growth (%) 108.00
SYN's EBITDA Growth (%) is ranked higher than
98% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -10.60 vs. SYN: 108.00 )
SYN' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 108
Current: 108

0
108
EPS Growth (%) 65.10
SYN's EPS Growth (%) is ranked higher than
96% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: -12.60 vs. SYN: 65.10 )
SYN' s 10-Year EPS Growth (%) Range
Min: 0   Max: 65.1
Current: 65.1

0
65.1
» SYN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

SYN Guru Trades in

Q2 2013

SYN Guru Trades in Q2 2013

Chuck Royce 428,669 sh (New)
» More
Q3 2013

SYN Guru Trades in Q3 2013

Chuck Royce 428,669 sh (unchged)
» More
Q4 2013

SYN Guru Trades in Q4 2013

Chuck Royce 778,000 sh (+81.49%)
» More
» Details

Insider Trades

Latest Guru Trades with SYN



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 9.69
SYN's P/B is ranked lower than
71% of the 787 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. SYN: 9.69 )
SYN' s 10-Year P/B Range
Min: 2.78   Max: 18.11
Current: 9.69

2.78
18.11

Valuation & Return

vs
industry
vs
history
Forward Rate of Return (Yacktman) -107.98
SYN's Forward Rate of Return (Yacktman) is ranked higher than
55% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. SYN: -107.98 )
SYN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0   Max: 0
Current: -107.98

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:SFYB.Germany
Synthetic Biologics Inc. was incorporated in the State of Nevada. The company is a biotechnology company engaged in the development of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses. It is developing an oral enzyme for the prevention of C. difficile infections, and a series of monoclonal antibody therapies for the treatment of Pertussis and Acinetobacter infections. In addition, the Company is developing a drug candidate for the treatment of relapsing-remitting multiple sclerosis and cognitive dysfunction in multiple sclerosis, and has partnered the development of a treatment for fibromyalgia. It competes with Actelion Pharmaceuticals, Bayer Health Care, Biogen Idec, Eli Lilly & Co., Genzyme, GlaxoSmithKline Pharmaceuticals, Merck & Co., Pfizer, Novartis, Teva Pharmaceuticals and United Therapeutics.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide